Literature DB >> 9634475

Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II.

D Bruniquel1, N Borie, S Hannier, F Triebel.   

Abstract

The lymphocyte activation gene-3 (LAG-3), a major histocompatibility complex (MHC) class II ligand evolutionarily related to CD4, is expressed exclusively in activated T and NK lymphocytes and seems to play a role in regulating the evolving immune response. We first determined that surface LAG-3 expression on activated human T cells is upregulated by certain cytokines (IL-2, IL-7, IL-12) and not by others (IL-4, IL-6, IL-10, TNF-alpha, TNF-beta, IFN-gamma). Surface LAG-3 expression correlated with intracellular IFN-gamma production in both CD4+ and CD8+ T-cell subsets. We then analyzed the 5' transcription control sequences of LAG-3. A DNase I hypersensitive site induced in T cells following cellular activation was found in the region including the transcriptional start site, showing that DNA accessibility is a mechanism which restricts LAG-3 expression to activated T cells. Transcription is initiated at three sites. A GC box, 80 base pairs (bp) upstream of the major transcription start site, forms a minimal promoter which is regulated by two upstream regions containing positive and negative regulatory elements with multiple protein binding sites as shown by footprinting analysis. In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements. Finally, a 100 bp region downstream of the transcription start site was shown to be involved in the cell-specific control of LAG-3 expression. Understanding this highly regulated expression may help to determine the intriguing role of this activation-induced MHC class II ligand.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634475     DOI: 10.1007/s002510050411

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  31 in total

1.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Authors:  Jun Wang; Miguel F Sanmamed; Ila Datar; Tina Tianjiao Su; Lan Ji; Jingwei Sun; Ling Chen; Yusheng Chen; Gefeng Zhu; Weiwei Yin; Linghua Zheng; Ting Zhou; Ti Badri; Sheng Yao; Shu Zhu; Agedi Boto; Mario Sznol; Ignacio Melero; Dario A A Vignali; Kurt Schalper; Lieping Chen
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

2.  Metalloproteases regulate T-cell proliferation and effector function via LAG-3.

Authors:  Nianyu Li; Yao Wang; Karen Forbes; Kate M Vignali; Bret S Heale; Paul Saftig; Dieter Hartmann; Roy A Black; John J Rossi; Carl P Blobel; Peter J Dempsey; Creg J Workman; Dario A A Vignali
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

3.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

4.  High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.

Authors:  Jana Kotaskova; Boris Tichy; Martin Trbusek; Hana Skuhrova Francova; Jitka Kabathova; Jitka Malcikova; Michael Doubek; Yvona Brychtova; Jiri Mayer; Sarka Pospisilova
Journal:  J Mol Diagn       Date:  2010-03-12       Impact factor: 5.568

5.  Induction of Inhibitory Receptors on T Cells During Plasmodium vivax Malaria Impairs Cytokine Production.

Authors:  Pedro A C Costa; Fabiana M S Leoratti; Maria M Figueiredo; Mauro S Tada; Dhelio B Pereira; Caroline Junqueira; Irene S Soares; Daniel L Barber; Ricardo T Gazzinelli; Lis R V Antonelli
Journal:  J Infect Dis       Date:  2015-05-27       Impact factor: 5.226

6.  Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.

Authors:  Christian H Poehlein; Daniel P Haley; Edwin B Walker; Bernard A Fox
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

Review 7.  Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Authors:  Jennifer A Wargo; Alexandre Reuben; Zachary A Cooper; Kevin S Oh; Ryan J Sullivan
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

8.  Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.

Authors:  Joseph F Grosso; Monica V Goldberg; Derese Getnet; Tullia C Bruno; Hung-Rong Yen; Kristin J Pyle; Edward Hipkiss; Dario A A Vignali; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

9.  LAG-3 regulates plasmacytoid dendritic cell homeostasis.

Authors:  Creg J Workman; Yao Wang; Karim C El Kasmi; Drew M Pardoll; Peter J Murray; Charles G Drake; Dario A A Vignali
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

10.  Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load.

Authors:  José Peña; Norman G Jones; Stephanie Bousheri; David R Bangsberg; Huyen Cao
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-26       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.